AzTrials
AzTrials

Knee InjuriesNCT06078072

Biomaterials and Mesenchymal Stem/Stromal Cells in the Treatment of Knee Articular Surface Lesions

An observational study of Knee Injuries and Cartilage Injury, run by University Medical Centre Ljubljana at 1 site in Slovenia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this observational study is to evaluate the combined single-step approach with biomaterials and mesenchymal stem/stromal cells in the treatment of knee articular surface lesions. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Biomaterials augmented with mesenchymal stem/stromal cells
Type of treatment
Surgery or procedure
How many people
90 participants
Where
1 siteSlovenia
Study dates
1 Sep 2022to 31 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Adult, Older adult

Study population: 100-150 adult patients (age:18-65) with knee articular surface lesions (size ≥ 1.5 cm2, ICRS grades 3-4) surgically treated with the combined single-step approach (scaffold and fBMA) between January 2013 and December 2020.

Who may be able to join

  • informed consent
  • patients treated with combined single-step procedure (scaffold and fBMA) for knee articular surface lesions, between January 2013 and December 2020
  • symptomatic knee articular surface lesions (International cartilage repair society (ICRS) grades 3-4, size ≥ 1.5 cm2) unresponsive to conservative treatment,
  • only mild concomitant osteoarthritis (Kellgren-Lawrence grades 1-2)

Who cannot join

  • patients that refuse to participate in the study
  • non responders to the invitation to answer PROMs at the follow-up
  • associated medical conditions (inflammatory, metabolic, neoplastic, etc.) that could directly handicap the musculoskeletal system or indirectly impact the quality of life

Trial locations and contacts

1 site in 1 country.

Slovenia1 site
  • University medical centre Ljubljana

    Ljubljana, 1000

Other trials in Slovenia

About this study

The goal of this observational study is to evaluate the combined single-step approach with biomaterials and mesenchymal stem/stromal cells in the treatment of knee articular surface lesions. The clinical analysis of the treatment outcomes, regarding postoperative improvements and safety, is going to be accompanied with laboratory analysis of the intraoperatively applied cellular products.

The main hypothesis are: (1) such combined single-step procedure significantly improves patients' functioning and quality of life; (2) this therapeutic approach is safe; (3) cellular parameters of the applied filtered bone marrow aspirate (fBMA) impact treatment outcomes, among other potential predictors.

Researchers will compare subjective (questionnaire) and objective (clinical examination) status of patients before and after the operation, record any potential complications and perform regression analysis to assess the influence of potential predictors on postoperative improvements.

Being tested
Biomaterials augmented with mesenchymal stem/stromal cells
Keywords
Biomaterials, Mesenchymal stem/stromal cells, Bone marrow aspirate, Cartilage, Osteochondral lesion, Knee
Medical subject headings
Knee Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Biomaterials augmented with mesenchymal stem/stromal cellsProcedure or surgery

    Combined single-step procedure of treating knee articular surface lesions with biomaterials (scaffolds) and mesenchymal stem cells (filtered bone marrow aspirate concentrate)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Knee injury and Osteoarthritis Outcome Score (KOOS) subscale Pain postoperative improvement

    Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patients' pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score 0 being the worst score and 100 indicating no impairment.

    KOOS subscale Pain postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.

    Paired Student t test will be applied to compare preoperative and postoperative values of KOOS subscale Pain.

    Measured: At least 24 months after the operation

Secondary outcomes (7)
  1. Knee injury and Osteoarthritis Outcome Score (KOOS) subscales postoperative improvements

    Originally published in 1998, the Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score 0 being the worst score and 100 indicating no impairment.

    KOOS subscales postoperative improvements will be calculated as differences between preoperative and postoperative scores at the final follow up. As secondary outcome measures will be calculated all KOOS subscales improvements, beside KOOS subscale Pain, which is determined as the primary outcome measure.

    Paired Student t test will be applied to compare preoperative and postoperative values of all KOOS subscales.

    Measured: At least 24 months after the operation

  2. Complications (SAE and GF)

    Serious adverse events (SAE) are defined as any hospitalization or revision surgery (arthrofibrosis, synovitis, infection, hardware problem, pulmonary embolism, etc.), while graft failures (GF) as revision surgery to the lesion or confirmed indication for it. SAE will be further classified as related (arthrofibrosis, synovitis, graft hypertrophy/delamination, etc.) or unrelated (hardware removal, meniscus or ligament injuries, new cartilage lesions, pulmonary embolism, etc.) to the graft.

    Measured: Recording until the final follow up (minimum 24 months after the operation)

  3. Cellular parameters of intraoperatively applied filtered Bone Marrow Aspirate (fBMA)

    Samples for cell counting (100 µl), fibroblast colony forming units (CFU-F) assay (1-2 ml) and flow cytometry (1-2 ml) will be taken before and after BMA processing with filter-based separation device. The total nucleated cell (TNC) count will be determined by counting white blood cells with hematology analyzer COULTER® Ac·T diff2™ (Beckman Coulter, Fullerton, CA, USA). MSCs content will be estimated with flow cytometry (FACSCalibur, BD Biosciences, San Jose, CA, USA) by determining CD271+ and CD45-cells, and concomitant assessment of their viability using 7-amino-actinomycin D (7-AAD) dye. Also, the CFU-F assay, which is a functional assay for measuring the frequency of MSCs with the colony forming abilities, will be performed. Briefly, cells will be seeded at least in duplicates into well culture plates and cultured in standard conditions: 37 °C, 5% CO2. After 14 days, colonies containing ≥ 50 fibroblastic cells will be manually counted under the stereomicroscope.

    Measured: Finsihed in 14 days after the procedure

  4. Tegner Activity Scale (TAS) postoperative improvement

    Tegner Activity Scale (TAS) is a one-item score that graded activity based on work and sports activities on a 11-level scale from 0 to 10. Zero represents disability because of the knee problems and 10 represents national or international level soccer.

    TAS postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.

    Paired Student t test will be applied to compare preoperative and postoperative values of TAS.

    Measured: At least 24 months after the operation

  5. European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) postoperative improvement

    EQ-5D-3L descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression . Each dimension has 3 levels: no problems, some problems, and extreme problems. The respondent is asked to indicate his or her health state by ticking the box that marks the most appropriate level of problems in each dimension. A unique health state can be described according to the responses to the 5 questions. Health states defined in this way may be converted into a single summary index by applying a formula that attaches values to each of the levels in each dimension. States can be converted to a single value where 1 is equivalent to full health and 0 to a state equivalent to death.

    EQ-5D-3L postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.

    Paired Student t test will be applied to compare preoperative and postoperative values of EQ-5D-3L .

    Measured: At least 24 months after the operation

  6. EuroQol Visual Analogue Scale (EQ-VAS) postoperative improvement

    EQ-VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100, where 0 represents the worst health state imaginable and 100 represents the best health state imaginable.

    EQ-VAS postoperative improvement will be calculated as difference between preoperative and postoperative scores at the final follow up.

    Paired Student t test will be applied to compare preoperative and postoperative values of EQ-VAS5.

    Measured: At least 24 months after the operation

  7. Potential predictors (patients' demographics, medical history, joint and lesions' characteristics, surgical and cellular parameters) of the clinical outcomes (KOOS subscales, EQ-5D-3L, EQ-VAS, TAS)

    Regression models will be used to assess the influence of proposed predictors (patients' demographics, medical history, joint and lesions' characteristics, surgical and cellular parameters) on the postoperative improvements in clinical outcome measures (KOOS subscales, EQ-5D-3L, EQ-VAS, TAS). Statistical analysis will be performed with SPSS (version 25.0; IBM, Chicago, IL, USA).

    Measured: At the time of statistical analysis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2023
  2. Study start1 Sep 2022
  3. Primary completion31 Aug 2023
  4. Study completion31 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06078072
Sponsor's protocol ID
University Medical Centre
Status last verified
Oct 2023
First submitted
2 Aug 2023
Last updated
30 Nov 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kolar M, Veber M, Girandon L, Drobnic M. A Biomimetic Osteochondral Scaffold Augmented With Filtered Bone Marrow Aspirate for the Treatment of Joint Surface Lesions in the Knee. Am J Sports Med. 2024 Jun;52(7):1826-1833. doi: 10.1177/03635465241247788. Epub 2024 May 20.

    PubMed 38767159

Questions about this trial

What is this clinical trial studying?

An observational study of Knee Injuries and Cartilage Injury, run by University Medical Centre Ljubljana at 1 site in Slovenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Knee injury and Osteoarthritis Outcome Score (KOOS) subscale Pain postoperative improvement (time frame: At least 24 months after the operation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06078072, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in